Core Viewpoint - The Zhejiang Securities Regulatory Bureau has issued a decision regarding Minsheng Securities Co., Ltd. for violations during its continuous supervision of Zhejiang Weikang Pharmaceutical Co., Ltd.'s initial public offering process [1] Group 1: Violations Identified - Minsheng Securities failed to adequately monitor the abnormal delays in construction projects and did not perform sufficient verification procedures [1] - The conclusions drawn in the continuous supervision documents for Weikang Pharmaceutical in 2023 were not cautious enough, indicating deficiencies in internal controls within the investment banking operations [1] Group 2: Regulatory Actions - The actions of Minsheng Securities violated Article 5, Paragraph 1 of the "Administrative Measures for Sponsorship of Securities Issuance and Listing" (CSRC Order No. 170) [1] - The responsible representatives, Ren Shaozhong and Zhong Desong, are held primarily accountable for the violations [1] - The Zhejiang Securities Regulatory Bureau has decided to issue a warning letter as an administrative regulatory measure against Minsheng Securities [1]